Add like
Add dislike
Add to saved papers

Mitigation of Cr(VI) toxicity using Pd-nanoparticles immobilized catalytic reactor (Pd-NICaR) fabricated via plasma and gamma radiation.

Catalytic reduction of Cr(VI) to less toxic Cr(III) form using metal nanoparticles is one of the novel approaches adopted to deal with Cr toxicity. In this work, we report the fabrication of a facile, reusable, and robust Pd nanoparticles-immobilized catalytic reactor (Pd-NICaR) system using green, environment-friendly gamma radiolytic, and plasma polymerization processes. A room temperature, RF-powered plasma polymerization process was employed to functionalize a polyethylene-polypropylene (PE-PP) non-woven matrix with epoxy group containing monomer 2,3-epoxypropyl methacrylate (EPMA). EPMA-functionalized PE-PP (EPMA-f-PE-PP) substrate was subsequently used as a template for in situ generation and immobilization of Pd NPs via gamma radiolytic route. The samples were characterized using FTIR, SEM, XPS, and XRF techniques. The catalytic efficacy of Pd-NICaR towards Cr(VI) reduction, in the presence of formic acid (FA) as a reductant, was investigated spectrophotometrically, and reaction parameters were optimized at reaction temperature of 50 °C and [FA]/[Cr(VI)] = 680 to achieve catalytic reduction efficiency of 99.7% within 10 min in batch process. The system showed excellent reusability (~ 20 cycles) and storage stability (> 30 days) without substantial loss (~ 11%) of activity. Practical applicability of the robust catalytic system towards Cr(VI) toxicity mitigation was established in continuous flow mode using a fixed-bed column reactor.

Full text links

We have located links that may give you full text access.
Can't access the paper?
Try logging in through your university/institutional subscription. For a smoother one-click institutional access experience, please use our mobile app.

Related Resources

For the best experience, use the Read mobile app

Mobile app image

Get seemless 1-tap access through your institution/university

For the best experience, use the Read mobile app

All material on this website is protected by copyright, Copyright © 1994-2024 by WebMD LLC.
This website also contains material copyrighted by 3rd parties.

By using this service, you agree to our terms of use and privacy policy.

Your Privacy Choices Toggle icon

You can now claim free CME credits for this literature searchClaim now

Get seemless 1-tap access through your institution/university

For the best experience, use the Read mobile app